SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced the appointment of Marcela Maus, M.D., Ph.D., and Athena Countouriotis, M.D., to its Board of Directors. Drs. Maus and Countouriotis bring deep expertise spanning cellular immunotherapy research, clinical development, and biotechnology company leadership. "We are thrilled to welcome Marcela and Athena to Umoja's Board of Directors," said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma. "Their complementary perspectives on scientific innovation and clinical development leadership will be invaluable as we continue to advance our VivoVecTM platform and clinical programs with the goal of expanding access to transformative CAR T therapies for patients." Marcela Maus, M.D., Ph.D., is a Professor of Medicine at Harvard Medical School, the Paula O'Keeffe Chair in Oncology and Director of Cellular Immunotherapy at The Krantz Family Center for Cancer Research at Massachusetts General Hospital, and ... Full story available on Benzinga.com
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
